Knight Therapeutics Inc T.GUD

Paladin Labs' Revenue Guidance (2007-2012)

[gudisgood]

Just went through some of Paladin Labs' revenue guidance. In the years that I checked, they beat the midpoint of their initial revenue guidance every year. Here are the relative guidance beats:

2007	4,9 %
2008	13,3 %
2009	9,7 %
2010	6,7 %
2011	6,8 %
2012	9,9 %

[MrMugsy]

Note:  If i recall over Paladin's 19 years, there were at least two periods where growth stalled and it took a year to regain the momentum. Now, they have a lot more cash and cash inflow frow which to attempt to maintain growth.  The first 8 years for GUD have been very impressive. Bigger growth than I ever saw could come in the 2025-2028 period - organically (my guess only). 

[gudisgood]

In 2003, revenue was almost even, other than that seemed to have been decent growth every year. Operating cash flow was a different case though... years of positive growth, negative growth and zero growth. Year Revenue Growth Op. Cash Flow Growth 1997            

[gudisgood]

Just noticed I have the 2012 revenue number is excluding Litha in my Excel. With Litha's numbers, revenues were $210 200.

[curiousj]

2013 number was $276 850 included the pharmaplan acq/litha

[curiousj]

gap still remains between Paladin's margins and Knight's. what's weighing on Knight is amortization is high and GM are low, they paid for GBT and license agreements have too high royalties. Further the GM% from exelon should of delivered a lot higher especially given the price paid 

[MrMugsy]

GUD knows what they purchased - they know the GM concerns and they know the work they need to do on the financial side.  Nothing drastic is happening overnight.  It's a process.  It's a very good team at work so I'm not losing sleep.  None of this is new to the key players here. Watching the EBITDA growth and the cash flow is key to operations as many other things